Delisting riskPopularity #4,408
Lisata Therapeutics (LSTA)
Develops certepetide for tumor-penetrating cancer therapy combinations.
$1.44
vs last close−0.04 (−3.04%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 12.09% | 1.09M shares | |
|---|---|---|---|
| 30 holders · as of Jun 30, 2026 | |||
| Insiders | 15.69% | 1.41M shares | |
| 10 holders · as of Aug 26, 2026 | |||
| Other | 72.22% | 6.51M shares | |
| remainder | |||
9.01M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
30 holders · 1.09M shares · 3 new positions · 12 increased · 4 reduced · 7 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 278.8K | 3.09% | +7.0K | Aug 13, 2026 |
| Yakira Capital Management, Inc. | 138.6K | 1.54% | +138.6Knew | Aug 13, 2026 |
| CSS LLC/IL | 110.4K | 1.23% | +48.5K | Aug 14, 2026 |
| Deltec Asset Management LLC | 83.2K | 0.92% | −6.8K | Jul 21, 2026 |
| Rangeley Capital, LLC | 81.0K | 0.90% | +6.0K | Aug 14, 2026 |
| Geode Capital Management, LLC | 72.6K | 0.81% | +1.7K | Aug 12, 2026 |
| Virtu Financial LLC | 58.8K | 0.65% | +16.6K | Aug 13, 2026 |
| BlackRock, Inc. | 54.9K | 0.61% | 0 | Aug 7, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Branham Justin Earl | 5.10% | 462.1K | 13G | Aug 26, 2026 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.